Skip to main content


Ian Read Chairman and Chief Executive Officer

Our commitment to a sustainable future is another way that Pfizer is working to make a positive impact in the lives of all who rely on us and to advance our purpose to innovate to bring patients therapies that significantly improve their lives.

In aiming to improve people’s lives through scientific innovation, Pfizer is committed to delivering on three of the 17 United Nations Sustainable Development Goals (SDGs) — Good Health and Well-Being, Climate Action, and Responsible Production. We believe these SDGs are vital in protecting human and environmental health, as well as preserving our planet’s precious natural resources.

At the core of Pfizer’s green journey are programs that apply innovative approaches to manage our impact on climate change, improve product stewardship, reduce waste and conserve water resources. Building on a 50 percent reduction in our greenhouse gas (GHG) emissions from 2000 to 2015,* Pfizer is moving forward toward our 2020 public targets to further reduce GHG by 20 percent, waste by 15 percent and water use by 5 percent. In addition, we are partnering with our key suppliers to strengthen their sustainability efforts.

As a long-time reducer of GHG, Pfizer recognizes that voluntary actions alone will not address climate change. Therefore, we support government policies that establish emissions reduction targets guided by the best available science to stabilize global temperature rise below 2 oC. As a result of our strong public commitments, Pfizer was one of the first 12 companies recognized by the We Mean Business initiative for having a Science Based Target aimed at stabilizing global temperature rise by 2050.

Many of today’s medicines, from cancer medications to rheumatoid arthritis treatments, could not be made without rare and expensive precious metal catalysts. Pfizer scientists are finding materials to replace these catalysts with more sustainable alternatives.

Through a Pfizer collaboration with the Bill & Melinda Gates Foundation and the Children’s Investment Fund Foundation, we are helping to broaden access to Pfizer’s long-acting injectable contraceptive, Sayana® Press (medroxyprogesterone acetate), for women most in need in some of the world’s poorest countries. The injection system consists of a small bubble of plastic attached to a needle. This design helps reduce waste, is discreet and can be easily transported. Since the product’s launch in 2014, more than 6 million doses of Sayana® Press have been shipped to 20 developing countries.

Our commitment to a sustainable future is another way that Pfizer is working to make a positive impact in the lives of all who rely on us and to advance our purpose to innovate to bring patients therapies that significantly improve their lives.

* Historic estimated GHG emissions reductions do not include Hospira operations.